GlassScriptPhysician profile
Angela Kim
NPI 1649711391
$6,466.44
in general payments reported to CMS, 2019-2025
25 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $566 · 2022: $1,413 · 2023: $3,688 · 2024: $689 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,258 · Food and Beverage: $1,575 · Travel and Lodging: $470 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,257.50 |
| Food and Beverage | $1,575.08 |
| Travel and Lodging | $470.01 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,141.78 | 2021-2024 | Sotyktu |
| Abbvie INC. | $395.72 | 2021-2025 | |
| Lilly USA, LLC | $357.15 | 2022-2023 | Taltz, Olumiant |
| Incyte Corporation | $329.61 | 2022-2023 | Opzelura |
| Galderma Laboratories, L.P. | $274.58 | 2021-2022 | |
| Genzyme Corporation | $226.56 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $210.40 | 2022-2024 | Dupixent |
| Janssen Biotech, INC. | $179.98 | 2022-2023 | Tremfya |
| Sun Pharmaceutical Industries INC. | $160.58 | 2022-2024 | |
| Arcutis Biotherapeutics, INC. | $146.94 | 2023 | |
| Dermavant Sciences, INC. | $136.31 | 2022-2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.31 | 2023 | Spevigo |
| Leo Pharma INC. | $107.78 | 2022 | |
| Janssen Scientific Affairs, LLC | $106.60 | 2022 | |
| Vyne Pharmaceuticals INC. | $106.00 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $85.55 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $78.06 | 2022 | |
| Pfizer INC. | $60.81 | 2024 | |
| Allergan, INC. | $60.09 | 2021 | |
| Revance Therapeutics, INC. | $56.24 | 2024 | Daxxify |
| Amgen INC. | $49.98 | 2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $22.18 | 2024 | |
| Verrica Pharmaceuticals INC. | $20.88 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.48 | 2021 | |
| Biofrontera INC. | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.